Remove 2022 Remove Hypertension Remove Pulmonary
article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Predictors of Outcomes in Mild Pulmonary Hypertension

American College of Cardiology

What is the impact on prognosis of the 2022 ESC/ERS pulmonary hypertension (PH) guidelines on the new redefined hemodynamic threshold for the diagnosis of precapillary PH?

article thumbnail

Association of pulmonary hypertension with the outcome in patients undergoing edge-to-edge mitral valve repair

Heart BMJ

Objectives The association of pulmonary hypertension (PH) with the outcome after mitral transcatheter edge-to-edge repair (M-TEER) focusing on the new ESC/ERS guidelines definition for PH. to 2.07); p<0.001 and 2022: HR 2.09 (95% CI 1.54 to 2.07); p<0.001 and 2022: HR 2.09 (95% CI 1.54 to 2.83); p<0.001).

article thumbnail

Noninvasive evaluation of pulmonary hypertension using the second heart sound parameters collected by a mobile cardiac acoustic monitoring system

Frontiers in Cardiovascular Medicine

Background Pulmonary hypertension (PH) is linked to higher rates of morbidity and mortality worldwide. The estimated pulmonary artery systolic pressure (ePASP ≥ 35 mmHg) measured by echocardiography helps screen PH patients. Early diagnosis of PH is important for clinical treatment.

article thumbnail

Right Ventricular?Vascular Uncoupling Predicts Pulmonary Hypertension in Clinically Diagnosed Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association

BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), and it is a strong predictor of adverse outcomes. Both resting/stress TAPSE/PASP and TAS’/PASP were correlated with rest/exercise pulmonary capillary wedge pressure and mean pulmonary artery pressure.

article thumbnail

Validation of Post-Capillary PH Definition in HF

American College of Cardiology

What is the impact and prognostic value of the new 2022 European guideline definition of post-capillary pulmonary hypertension (pcPH) in heart failure (HF), which lowered the level of mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR)?

article thumbnail

Prognostic implications of pulmonary vascular resistance in transcatheter aortic valve implantation

Heart BMJ

Pulmonary hypertension (PH) is a complex and progressive disorder characterised by elevated pulmonary artery pressure. In 2022, the most recent update of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) guidelines for PH presented a redefinition of the haemodynamic criteria for its diagnosis.